Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INTS
stocks logo

INTS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.050
-77.27%
--
--
-0.057
-74.24%
--
--
-0.057
-56.41%
Estimates Revision
The market is revising No Change the revenue expectations for Intensity Therapeutics, Inc. (INTS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 63.17%.
EPS Estimates for FY2025
Revise Downward
down Image
-6.18%
In Past 3 Month
Stock Price
Go Up
up Image
+63.17%
In Past 3 Month
Wall Street analysts forecast INTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTS is 3.33 USD with a low forecast of 1.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast INTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTS is 3.33 USD with a low forecast of 1.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.460
sliders
Low
1.50
Averages
3.33
High
5.00
Current: 0.460
sliders
Low
1.50
Averages
3.33
High
5.00
Benchmark
Robert Wasserman
Speculative Buy
downgrade
$4
2025-08-20
Reason
Benchmark
Robert Wasserman
Price Target
$4
2025-08-20
downgrade
Speculative Buy
Reason
Benchmark analyst Robert Wasserman lowered the firm's price target on Intensity Therapeutics to $1.50 from $4 and keeps a Speculative Buy rating on the shares after the company reported Q2 results and provided an update on their clinical pipeline. The firm cites recent share dilution for its revised price target.
Brookline
Hold
to
Buy
upgrade
$3
2025-08-12
Reason
Brookline
Price Target
$3
2025-08-12
upgrade
Hold
to
Buy
Reason
Brookline upgraded Intensity Therapeutics to Buy from Hold with a $3 price target following Q2 results. Raising $11M extends the cash runway to the second half of 2026, notes the firm, which also cites the advancement of the Phase 2 triple negative breast cancer trial. The firm foresees "a favorable risk-reward as INT230-6 advances through the clinic," the analyst tells investors.
ThinkEquity
NULL -> Buy
initiated
$3
2025-07-28
Reason
ThinkEquity
Price Target
$3
2025-07-28
initiated
NULL -> Buy
Reason
ThinkEquity initiated coverage of Intensity Therapeutics with a Buy rating and $3 price target. The company has pivoted its clinical focus, creating a "high-risk, high-reward investment opportunity" centered around a near-term catalyst, the analyst tells investors in a research note. The sees a "compelling opportunity" into the Phase 2 INVINCIBLE-4 study evaluating Intensity's lead asset, INT230-6, in neoadjuvant triple-negative breast cancer.
Alliance Global Partners
Buy
downgrade
2025-05-22
Reason
Alliance Global Partners
Price Target
2025-05-22
downgrade
Buy
Reason
Alliance Global Partners lowered the firm's price target on Intensity Therapeutics to $3.50 from $8.50 and keeps a Buy rating on the shares. The price target reduction reflects the trial delay for INT230-6 for soft tissue sarcoma, the analyst tells investors in a research note. The trial is being paused until further notice due to funding constraints, and the firm believes it will take a major funding event to get it back on track.
Brookline
analyst
Buy -> Hold
downgrade
2025-05-19
Reason
Brookline
analyst
Price Target
2025-05-19
downgrade
Buy -> Hold
Reason
Brookline downgraded Intensity Therapeutics to Hold from Buy and suspended the firm's price target pending visibility into additional funding. A global Phase 3 open label, randomized, superiority trial is ongoing in metastatic sarcoma, evaluating INT230-6 monotherapy as an intratrumoral treatment compared to the standard of care in second and third line treatment in soft tissue sarcoma subtypes, notes the analyst, who points out that enrollment completion is expected in the first half of 2026, with data readouts expected based on the number of deaths in the trial.
Alliance Global Partners
James Molloy
Strong Buy
Initiates
$8.5
2025-01-13
Reason
Alliance Global Partners
James Molloy
Price Target
$8.5
2025-01-13
Initiates
Strong Buy
Reason
Alliance Global Partners initiated coverage of Intensity Therapeutics with a Buy rating and $8.50 price target. Intensity is developing INT230-6, a Phase 3 asset that both decreases the tumor burden while also activating an increased immune system response to better recognize and target the cancer, for advanced soft tissue sarcoma and triple negative breast cancer. The firm values INT230-6 for STS at $6 per share, INT230-6 for TNBC at $2 per share, and the remaining compounds and cash at 50c per share, the analyst noted.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Intensity Therapeutics Inc (INTS.O) is -2.09, compared to its 5-year average forward P/E of -3.27. For a more detailed relative valuation and DCF analysis to assess Intensity Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.27
Current PE
-2.09
Overvalued PE
-0.99
Undervalued PE
-5.54

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

INTS News & Events

Events Timeline

(ET)
2025-11-06
16:45:11
Intensity Therapeutics announces Q3 earnings per share of 6 cents compared to a loss of 25 cents last year.
select
2025-10-31 (ET)
2025-10-31
08:07:52
Intensity Therapeutics sets price at 80 cents for 5 million shares in registered direct offering
select
2025-10-30 (ET)
2025-10-30
07:39:45
Study Highlights Antitumor Effects of Intensity Therapeutics' INT230-6
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
11-01Benzinga
Dow Drops More Than 100 Points as Amazon Reports Positive Q3 Results

  • Market Performance: U.S. stocks showed mixed results, with the Dow Jones falling 0.30%, while the NASDAQ rose 0.27%. Consumer discretionary shares increased by 3.8%, but utilities stocks dropped by 1.2%.

  • Amazon's Financial Results: Amazon reported strong third-quarter net sales of $180.2 billion, exceeding expectations, and projected fourth-quarter sales between $206.0 billion and $213.0 billion.

  • Notable Stock Movements: AMTD Digital's shares surged 99% after a significant revenue increase, while Luminar Technologies' shares plummeted 49% following an SEC subpoena and guidance suspension.

  • Global Market Trends: European shares declined, with the eurozone's STOXX 600 down 0.51%, and Asian markets mostly closed lower, except for Japan's Nikkei 225, which gained 2.12%.

[object Object]
Preview
9.5
10-31Benzinga
Nasdaq Rises More Than 1%; Apple Reports Earnings Exceeding Expectations

  • U.S. Stock Market Performance: U.S. stocks opened higher, with the Nasdaq Composite gaining over 1%, while the Dow and S&P 500 also saw modest increases. Consumer discretionary shares rose significantly by 4.3%, contrasting with a 1.1% decline in materials stocks.

  • Apple's Strong Financial Results: Apple Inc. reported better-than-expected fourth-quarter results, with revenue of $102.47 billion and earnings of $1.85 per share, surpassing analyst estimates.

  • Notable Stock Movements: EPWK Holdings saw a dramatic 137% increase in shares, while Getty Images surged 45% after a licensing agreement. Conversely, Luminar Technologies dropped 34% following an SEC subpoena, and OneSpan Inc. fell 26% due to disappointing sales results.

  • Global Market Trends: European shares declined, with the eurozone's STOXX 600 down 0.5%, while Asian markets mostly closed lower, despite Japan's Nikkei 225 gaining 2.12%.

[object Object]
Preview
9.0
10-31Yahoo Finance
Intensity Therapeutics Shares Surge Nearly 400% Following Promising Solid Tumor Results

  • Stock Performance: Intensity Therapeutics’ stock surged nearly 400% following promising results from its oncology candidate INT230-6, which demonstrated a 75% disease control rate and a median overall survival of 11.9 months in a Phase I/II trial.

  • Clinical Trial Results: The trial showed significant improvements in overall survival, particularly in metastatic sarcoma patients, where the median overall survival reached 21.3 months, and an abscopal effect was observed in 20% of patients treated with higher doses.

  • Immune Response: Notable increases in activated CD4+ and CD8+ T cells were found in the tumor microenvironment, indicating the potential for INT230-6 to elicit both local and systemic anti-cancer activity.

  • Future Trials: Intensity Therapeutics has initiated Phase III trials for INT230-6, including studies in sarcoma and triple-negative breast cancer, while reporting no dose-limiting toxicities in the trial participants.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Intensity Therapeutics Inc (INTS) stock price today?

The current price of INTS is 0.4603 USD — it has increased 12.2 % in the last trading day.

arrow icon

What is Intensity Therapeutics Inc (INTS)'s business?

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.

arrow icon

What is the price predicton of INTS Stock?

Wall Street analysts forecast INTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTS is 3.33 USD with a low forecast of 1.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Intensity Therapeutics Inc (INTS)'s revenue for the last quarter?

Intensity Therapeutics Inc revenue for the last quarter amounts to -2.73M USD, decreased -23.45 % YoY.

arrow icon

What is Intensity Therapeutics Inc (INTS)'s earnings per share (EPS) for the last quarter?

Intensity Therapeutics Inc. EPS for the last quarter amounts to -2387000.00 USD, decreased -39.90 % YoY.

arrow icon

What changes have occurred in the market's expectations for Intensity Therapeutics Inc (INTS)'s fundamentals?

The market is revising No Change the revenue expectations for Intensity Therapeutics, Inc. (INTS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 63.17%.
arrow icon

How many employees does Intensity Therapeutics Inc (INTS). have?

Intensity Therapeutics Inc (INTS) has 5 emplpoyees as of December 05 2025.

arrow icon

What is Intensity Therapeutics Inc (INTS) market cap?

Today INTS has the market capitalization of 27.58M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free